Indication
Gastroenteropancreatic Neuroendocrine Carcinoma
1 clinical trial
1 product
Product
PT217Clinical trial
A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3.Status: Recruiting, Estimated PCD: 2025-01-01